NASDAQ$PROK
ProKidney Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
ProKidney reported business updates and financial results.
ProKidney ended the first quarter of 2024 with $329 million in cash and cash equivalents. The company is on schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024.
- Final results from RMCL-002 Phase 2 trial to be presented at the European Renal Association (ERA) Congress on May 25, 2024.
- The PROACT 1 Phase 3 study (REGEN-006) protocol amendment has been completed and was submitted to the FDA in late March.
- Ulrich Ernst, Ph.D was appointed as Executive Vice President of Technical Operations.
- Lucio Tozzi was appointed as Senior Vice President of Global Clinical Operations.
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$0
Forward guidance
ProKidney expects that its existing cash, cash equivalents and marketable securities held on March 31, 2024, will enable them to fund operating expenses and capital expenditure requirements into the fourth quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2024
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro